Levi & Korsinsky, LLP announces that an RVNC class action lawsuit has been filed on behalf of investors who purchased Revance Therapeutics, Inc. (RVNC) securities between November 25, 2019, and October 11, 2021 For more on the RVNC Lawsuit please contact us today.

According to the Revance lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:  (i) quality control deficiencies existed at the Company’s manufacturing facility for DaxibotulinumtoxinA for Injection (“DXAI”); (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration (“FDA”) would approve the DAXI Biologics License Application (“BLA”) in its current form; (iii) accordingly, it was unlikely that the DAXI BLA would obtain FDA approval within the timeframe the Company had represented to investors; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

TO LEARN MORE ABOUT THE RVNC CLASS ACTION LAWSUIT, CLICK HERE

If you suffered a loss in Revance you have until February 8, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com